By Zacks Equity Research
On Apr 11, we updated our research report onNuVasive, Inc. NUVA, a leading player in the global spine market, focused on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The stock currently carries a Zacks Rank #3 (Hold).
NuVasive expects its international business to grow by 38% at CER in 2016. Additionally, management believes that, despite some sales disruption in the fourth quarter, international growth will largely be buoyed by the company’s strategy of refocusing on market penetration over the long haul. NuVasive expects to see positive momentum from these efforts starting from the first quarter of 2016.
